🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Treasury Wine Estates Shares Rise on Hopes of Australian Wine Tariff Removal in China

Published 10/23/2023, 12:50 PM
© Reuters.
AXJO
-
TSRYF
-

Shares of Treasury Wine Estates (OTC:TSRYF) Ltd (ASX: TWE) rose by 5.3% to A$12.390 on Monday, making it the third major riser in the ASX 200 index. The surge followed the announcement of a swift review of tariffs on Australian wine exports to China by the Australian government.

The company is preparing for a business resurgence in China, contingent on the removal of these tariffs. The impending tariff review is expected to last five months. Once the tariffs are removed, Treasury Wine Estates has plans to reallocate parts of its Penfolds Luxury and Icon (NASDAQ:ICLR) tiers from other global markets to China.

According to InvestingPro, Treasury Wine Estates is currently trading at a high earnings multiple with a P/E Ratio of 33.64, indicating that investors are willing to pay a higher price for its earnings. Despite the fact that the company's revenue has been declining at an accelerating rate, with a Revenue Growth of -1.72 % LTM2023.Q4, the company's liquid assets exceed its short-term obligations, suggesting it has enough resources to meet its short-term liabilities.

In addition to this strategic reallocation, the company aims to strengthen its sales and marketing strategies in China, with a view to rejuvenating Penfolds' distribution footprint there. This strategy is backed by InvestingPro Tips, which indicates that the company operates with a moderate level of debt and is predicted to be profitable this year.

This positive news for Treasury Wine Estates came on a day when the broader ASX200 declined, with only the healthcare and consumer staples sectors recording gains. Other notable events included ClearVue Technologies (ASX: CPV) securing $30 million funding from Alpha Investment Partners for its solar panel windows project, and Immutep (NASDAQ:IMMP) (ASX: IMM) shares surging after successful results from its phase II combination trial for metastatic non-small-cell lung cancer.

For more insights and tips on investing, you can check out InvestingPro's platform, which contains additional tips that can help investors make informed decisions. You can access it here.

The company's current market capitalization, adjusted for certain factors, is 5430M USD. Over the past year, the company's share price has experienced a total return of -5.48%, according to InvestingPro data. However, the company's shares are currently trading at 73.24% of their 52-week high, indicating some potential for growth.

InvestingPro's Fair Value for the company's shares is 7.43 USD, suggesting that the shares are currently undervalued. This could present a potential opportunity for investors looking for value investments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.